Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Haviland Enviro Corp V.HEC


Primary Symbol: V.HEC.P

Haviland Enviro Corp. is a Canada-based capital pool company. The principal business of the Company is the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. The Company has not commenced its business operations and has not generate any revenue.


TSXV:HEC.P - Post by User

Bullboard Posts
Post by iminddoon Jan 31, 2002 1:21pm
1319 Views
Post# 4712638

national bank

national bankLooks like nat'l bank trying everything to get prices to drop. Wsan't she the same one who gave us a very bad report a few month ago. I guess BPUR had Fuaerstin and we have Ntantoulis. Lets make sure she does not get her shares. "National Bank analyst Dimi Ntantoulis wrote in a morning note that the company is being too aggressive in forecasting the time to complete the studies, suggesting that the fourth quarter of 2002 is a more reasonable expectation. ``We see further potential disappointment in the short term as we do not believe Health Canada will approve Hemolink and certainly did not approve Hemolink in 2001 despite assurances from the company,'' wrote Ntantoulis. ``We believe the company will have to raise additional capital in the near term to finance its U.S. phase three trials. We recommend investors to take profits at these levels,'' she added."
Bullboard Posts